MDS

Oncology·MeSH: Recurrence

30 drugs in development·25 companies·7 clinical trials

Drug Pipeline by Phase

Approved(6)

Drug	Company
azacitidine	Amneal Pharmaceuticals, Inc. (AMRX)
EVRENZO (爱瑞卓®) / roxadustat	KYNTRA BIO INC. (KYNB)
lenalidomide	Mylan II B.V. (MYL)
promacta	Novartis AG (NVS)
reblozyl	ACCELERON PHARMA INC (XLRN)
rytelo	GERON CORP (GERN)

Phase 3(5)

Drug	Company
elritercept (KER-050)	Keros Therapeutics, Inc. (KROS)
Erythropoiesis-stimulating agents	BRISTOL MYERS SQUIBB CO (BMY)
luspatercept	CELGENE CORP /DE/ (CELG)
Luspatercept	BRISTOL MYERS SQUIBB CO (BMY)
roxadustat	KYNTRA BIO INC. (KYNB)

Phase 2(5)

Drug	Company
abv-1702	ABVC BIOPHARMA, INC. (ABVC)
AG-946	AGIOS PHARMACEUTICALS, INC. (AGIO)
Elritercept	Merus N.V. (MRUS)
etavopivat	Forma Therapeutics Holdings, Inc. (FMTX)
Glasdegib	Jazz Pharmaceuticals plc (JAZZ)

Phase 1(7)

Drug	Company
ACLX-002	Arcellx, Inc. (ACLX)
cb-5339	CASI Pharmaceuticals, Inc (DE) (CASI)
CLN-049	Cullinan Therapeutics, Inc. (CGEM)
DVX201 (Unmodified Natural Killer Cells)	Coeptis Therapeutics Holdings Inc. (COEP)
gtb-3650	GT Biopharma, Inc. (GTBP)
magrolimab	Forty Seven, Inc. (FTSV)
senti-202	Senti Biosciences, Inc. (SNTI)

Preclinical(2)

Drug	Company
CPI-182	Corvus Pharmaceuticals, Inc. (CRVS)
gtb-3550	GT Biopharma, Inc. (GTBP)

Unknown(2)

Drug	Company
hypomethylating agents	BRISTOL MYERS SQUIBB CO (BMY)
reb blood cell transfusion	BRISTOL MYERS SQUIBB CO (BMY)

Phase 1/Phase 2(2)

Drug	Company
nkx101	Nkarta, Inc. (NKTX)
r289	RIGEL PHARMACEUTICALS INC (RIGL)

Phase 2/Phase 3(1)

Drug	Company
Actimab-A	Actinium Pharmaceuticals, Inc. (ATNM)

BioSniper tracks 30 drugs in development for MDS across 25 companies.

There are 7 clinical trials targeting MDS tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.